With our unique Blockmer-based oligonucleotide synthesis technology, we offer extremely high purity oligonucleotides in mg to ton scale at reasonable prices.
・Oligonucleotide Synthesis Service
・Blockmer™ intermediates Sales
・Joint development of equipments and synthetic technologies related to oligonucleotide production
Masanori is an expert in nucleic acid chemistry. He has developed many technologies in nucleotides synthetic field, including liquid-phase synthesis of oligonucleotide APIs, solid-phase synthesis of oligonucleotide without base protection, Lewis base/Brønstead acid complex catalysts for phosphoroamidite condensation, full-base modification to nucleic acid on solid material, and methods for the synthesis of Bio-active nucleotides in water.
He worked as an assistant professor at Chemical Instrument Center of Nagoya University, an assistant professor at the Research Center for Computational Science, National Institutes of Natural Sciences, and a Research associate professor at Innovative Marine Technology, Kochi University before assuming his current position. He is also a visiting professor at Kobe University.
Masanori received his Ph.D. at Nagoya University, Japan.
Ichiro joined RaQualia Drug Discovery after serving as a researcher at Ciba-Geigy, head of the Chemistry Research Department at GSK Tsukuba Research Laboratories, and head of the Drug Discovery Chemistry Research Department 2 at Pfizer's Nagoya Research Laboratories. Later, he served as a specially appointed professor at the Kobe University Industry-Academia Collaboration Creation Division and the Graduate School of Science, Technology and Innovation, Kobe University. He has an extensive network with foreign pharmaceutical companies.
Responsible for the overall technical department.
Ichiro received his Ph.D. at UC Berkeley, USA.
Yosuke has nearly 10 years management experience in academia-based startups as the founder and CEO at Vasculead and head of corporate strategy at Quantum Biosystems. Also his international technology and business experiences include electrical engineering, business planning and R&D team management at Canon Inc. and Canon China for 11 years in total.
Yosuke received his B.A. and M.A. at Electrical engineering at Doshisha University, Japan, and MBA at Stephen M. Ross School of Business, the University of Michigan, USA.
Ryosuke worked as a consultant at SIGMAXYZ Inc. in charge of DX, change management, and channel strategy development for a major pharmaceutical company, a foreign CRO, and a foreign life insurance company.
He leads business model formulation as a member of the Business Model Subcommittee of the Healthcare IoT Consortium in 2019.
Also he has supported business model development based on technology seeds from domestic pharmaceutical companies and academia in the acceleration program BRAVE hosted by Beyond Next Ventures and Blockbuster TOKYO hosted by the Tokyo Metropolitan Government.
Ryosuke received his M.A. at Kyoto University (former Institute for Virus Research), Japan.
Takuma worked in the Cabinet Secretariat, the General Affairs Agency, the Ministry of Foreign Affairs, and Japanese embassies abroad. After returning to Japan, he has been involved in the management and revitalization of ventures and operating companies in Japan, the U.S., and Europe in the fields of biotechnology, pharmaceuticals, nanotechnology, and services.
In the pharmaceutical and biotech fields, his experience ranges from founding university-launched ventures to post-IPO management and business expansion.
Takuma received his B.A. at The University of Tokyo, Japan, and MBA at the University of Michigan's School of Public Policy and the University of Pennsylvania's Wharton School, USA.